Related references
Note: Only part of the references are listed.Patient-derived xenograft models in hepatopancreatobiliary cancer
Binhua Pan et al.
CANCER CELL INTERNATIONAL (2022)
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia
Eytan M. Stein et al.
CLINICAL CANCER RESEARCH (2022)
Early Tumor Size Reduction of at least 10% at the First Follow-Up Computed Tomography Can Predict Survival in the Setting of Advanced Melanoma and Immunotherapy
Haidara Almansour et al.
ACADEMIC RADIOLOGY (2022)
Physiologically-Based Pharmacokinetic Modeling to Support Determination of Bioequivalence for Dermatological Drug Products: Scientific and Regulatory Considerations
Eleftheria Tsakalozou et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
Application of Physiologically Based Pharmacokinetic Modeling in Preclinical Studies: A Feasible Strategy to Practice the Principles of 3Rs
Yawen Yuan et al.
FRONTIERS IN PHARMACOLOGY (2022)
Optimized scaling of translational factors in oncology: from xenografts to RECIST
Marcus Baaz et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2022)
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Qianyu Wang et al.
CANCERS (2022)
In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part II
Jakub Witkowski et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Melanoma metastasis: What role does melanin play? (Review)
Anoosha Saud et al.
ONCOLOGY REPORTS (2022)
Translational Modeling of Anticancer Efficacy to Predict Clinical Outcomes in a First-in-Human Phase 1 Study of MDM2 Inhibitor HDM201
Nelson Guerreiro et al.
AAPS JOURNAL (2021)
Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment
Hui Qin Wang et al.
CANCER RESEARCH (2021)
Thinking Differently about Cancer Treatment Regimens
Jeff Settleman et al.
CANCER DISCOVERY (2021)
Recent developments in in vitro and in vivo models for improved translation of preclinical pharmacokinetics and pharmacodynamics data
Jaydeep Yadav et al.
DRUG METABOLISM REVIEWS (2021)
The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity
Jiajia Zhou et al.
NATURE IMMUNOLOGY (2021)
The Combination of Cell Cultured Technology and In Silico Model to Inform the Drug Development
Zhengying Zhou et al.
PHARMACEUTICS (2021)
The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment
Yanghong Ni et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BOF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib
Philippe Saiag et al.
EUROPEAN JOURNAL OF CANCER (2021)
Translational Model-Informed Approach for Selection of Tuberculosis Drug Combination Regimens in Early Clinical Development
Budi O. Susanto et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma
Didier Decaudin et al.
EUROPEAN JOURNAL OF CANCER (2020)
In vitro to in vivo translation
William B. Mattes
CURRENT OPINION IN TOXICOLOGY (2020)
The role of mouse tumour models in the discovery and development of anticancer drugs
Christopher R. Ireson et al.
BRITISH JOURNAL OF CANCER (2019)
Melanin presence inhibits melanoma cell spread in mice in a unique mechanical fashion
Michal Sarna et al.
SCIENTIFIC REPORTS (2019)
Translation of in vitro findings to patients with asthma: a timely and compelling challenge
Pieter S. Hiemstra et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
Douglas D. Fang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma
Chiao-En Wu et al.
CANCERS (2019)
Murine stroma adopts a human-like metabolic phenotype in the PDX model of colorectal cancer and liver metastases
Arnaud Blomme et al.
ONCOGENE (2018)
Optimal Therapy Scheduling Based on a Pair of Collaterally Sensitive Drugs
Nara Yoon et al.
BULLETIN OF MATHEMATICAL BIOLOGY (2018)
Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective
Mohamad Shebley et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Evaluation and translation of combination therapies in oncology - A quantitative approach
Tim Cardilin et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
Georgina Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201
Sebastien Jeay et al.
CANCER RESEARCH (2018)
A multi-state model of chemoresistance to characterize phenotypic dynamics in breast cancer
Grant R. Howard et al.
SCIENTIFIC REPORTS (2018)
Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma Pooled Analysis of 4 Randomized Clinical Trials
Axel Hauschild et al.
JAMA ONCOLOGY (2018)
Effect of coadministration of rifampicin on the pharmacokinetics of linezolid: clinical and animal studies
Satsuki Hashimoto et al.
JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES (2018)
Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma
Hitesh B. Mistry et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Tumor Static Concentration Curves in Combination Therapy
Tim Cardilin et al.
AAPS JOURNAL (2017)
Tumor Microenvironment and Differential Responses to Therapy
Eishu Hirata et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma
M. S. Chatterjee et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma
Daniele Ouellet et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Precision-cut intestinal slices: alternative model for drug transport, metabolism, and toxicology research
Ming Li et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
PBPK modeling and simulation in drug research and development
Xiaomei Zhuang et al.
ACTA PHARMACEUTICA SINICA B (2016)
Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations
D. R. Mould et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2015)
Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours
Cathrine Leonowens et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Novel pre-clinical methodologies for pharmacokinetic drug-drug interaction studies: spotlight on humanized'' animal models
Swati Jaiswal et al.
DRUG METABOLISM REVIEWS (2014)
Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers
May Y. K. Ho et al.
XENOBIOTICA (2014)
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Manuel Hidalgo et al.
CANCER DISCOVERY (2014)
Comprehensive study on regional human intestinal permeability and prediction of fraction absorbed of drugs using the Ussing chamber technique
Asa Sjoberg et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
The role of tumour-stromal interactions in modifying drug response: challenges and opportunities
Douglas W. McMillin et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development
H. M. Jones et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
Change in Tumor Size by RECIST Correlates Linearly With Overall Survival in Phase I Oncology Studies
Rajul K. Jain et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
Jeffrey R. Infante et al.
LANCET ONCOLOGY (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Application of PBPK modelling in drug discovery and development at Pfizer
Hannah M. Jones et al.
XENOBIOTICA (2012)
Prediction of Human Renal Clearance from Preclinical Species for a Diverse Set of Drugs That Exhibit Both Active Secretion and Net Reabsorption
Stuart W. Paine et al.
DRUG METABOLISM AND DISPOSITION (2011)
Use of In Vivo Animal Models to Assess Pharmacokinetic Drug-Drug Interactions
Cuyue Tang et al.
PHARMACEUTICAL RESEARCH (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Rate of growth in melanomas - Characteristics and associations of rapidly growing melanomas
Wendy Liu et al.
ARCHIVES OF DERMATOLOGY (2006)
Changes in intratumor heterogeneity in blood perfusion in intradermal human melanoma xenografts during tumor growth assessed by DCE-MRI
BA Graff et al.
MAGNETIC RESONANCE IMAGING (2005)
Assessment of tumor blood perfusion by high-resolution dynamic contrast-enhanced MRI: A preclinical study of human melanoma xenografts
IC Benjaminsen et al.
MAGNETIC RESONANCE IN MEDICINE (2004)
Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase
HM Koo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Share Paper
